Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr:135:102921.
doi: 10.1016/j.ctrv.2025.102921. Epub 2025 Mar 10.

First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis

Fausto Petrelli  1 , Valentina Riboldi  2 , Lorenza Bruschieri  2 , Antonella Villa  3 , Fulvia Milena Cribiu'  4 , Karen Borgonovo  5 , Mara Ghilardi  5 , Antonio Ghidini  6 , Silvia Seghezzi  7 , Agostina De Stefani  2 , Francesca Trevisan  2
Affiliations

First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis

Fausto Petrelli et al. Cancer Treat Rev. 2025 Apr.

Abstract

Introduction: Locally advanced cervical carcinoma (LACC) remains a significant global health issue, particularly in low- and middle-income countries (LMICs), where disease burden is highest. While cisplatin-based chemoradiotherapy (CTRT) has long been the cornerstone of first-line treatment, its toxicities, including nephrotoxicity and hematologic adverse events, limit its use in certain patients. Advances in systemic therapies, including immune checkpoint inhibitors and induction chemotherapy, offer new avenues for improving outcomes. This study aimed to evaluate the efficacy of various first-line regimens for LACC through a systematic review and Bayesian network meta-analysis (NMA), focusing on overall survival (OS) and progression-free survival (PFS).

Materials and methods: This analysis adhered to PRISMA guidelines and included Phase III randomized controlled trials (RCTs) evaluating first-line treatments for LACC. The primary outcome was OS, expressed as hazard ratios (HRs) with 95% confidence intervals (CIs), while PFS was secondary. A comprehensive search of PubMed, EMBASE, and Cochrane Library was conducted through November 2024. Statistical analysis used a Bayesian NMA framework, with treatments ranked by surface under the cumulative ranking curve (SUCRA).

Results: Pembrolizumab + CTRT improved OS (HR, 0.67; 95 % CI, 0.50-0.90), while induction chemotherapy with carboplatin/paclitaxel followed by CTRT showed significant benefit (HR, 0.60; 95 % CI, 0.40-0.90). RT + cisplatin and 5-fluorouracil (5-FU) also improved OS (HR, 0.66; 95 % CI, 0.44-0.99), ranking highest in SUCRA analysis (98 %).

Conclusion: Three promising strategies-pembrolizumab-based regimens, induction chemotherapy followed by CTRT, and RT + CDDP + 5-FU-offer substantial survival benefits, advancing treatment options for LACC.

Keywords: Cervical cancer; Chemoradiotherapy; Locally advanced; Network meta-analysis; Pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types

MeSH terms